883 related articles for article (PubMed ID: 19114874)
1. Cardiovascular manifestations of insulin resistance.
Chahwala V; Arora R
Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
[TBL] [Abstract][Full Text] [Related]
2. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors.
Edelman SV
Rev Cardiovasc Med; 2003; 4 Suppl 6():S29-37. PubMed ID: 14668701
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
4. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
5. The clinical implications of insulin resistance.
Peters AL
Am J Manag Care; 2000 Aug; 6(13 Suppl):S668-74; discussion S675-81. PubMed ID: 11183420
[TBL] [Abstract][Full Text] [Related]
6. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.
Durbin RJ
Diabetes Obes Metab; 2004 Jul; 6(4):280-5. PubMed ID: 15171752
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
8. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
9. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
Betteridge DJ
Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
[TBL] [Abstract][Full Text] [Related]
10. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
Fonseca VA
Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic implications of diabetes in cardiovascular disease.
Cherian B; Meka N; Katragadda S; Arora R
Am J Ther; 2009; 16(6):e51-9. PubMed ID: 19940606
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
13. Metformin and pioglitazone: Effectively treating insulin resistance.
Staels B
Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
[TBL] [Abstract][Full Text] [Related]
14. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
Seufert J
Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
16. [Epidemiology of cardio-vascular complications of diabetes].
Grimaldi A; Heurtier A
Diabetes Metab; 1999 Jun; 25 Suppl 3():12-20. PubMed ID: 10421988
[TBL] [Abstract][Full Text] [Related]
17. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
18. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
Mazzone T
Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
[TBL] [Abstract][Full Text] [Related]
19. Lifestyle modification and endothelial function in obese subjects.
Hamdy O
Expert Rev Cardiovasc Ther; 2005 Mar; 3(2):231-41. PubMed ID: 15853597
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
Langenfeld MR; Forst T; Hohberg C; Kann P; Lübben G; Konrad T; Füllert SD; Sachara C; Pfützner A
Circulation; 2005 May; 111(19):2525-31. PubMed ID: 15883215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]